187 related articles for article (PubMed ID: 22552250)
21. WOC nurse consult: peristomal complication.
Kelly C
J Wound Ostomy Continence Nurs; 2012; 39(4):425-7. PubMed ID: 22772719
[No Abstract] [Full Text] [Related]
22. Peristomal pyoderma gangrenosum with high serum levels of interleukin-8.
Nakajima N; Kozaru T; Fukumoto T; Izumiyama T; Iwasashi H; Oka M
J Dermatol; 2018 Nov; 45(11):e297-e298. PubMed ID: 29701259
[No Abstract] [Full Text] [Related]
23. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum.
Triantafillidis JK; Cheracakis P; Sklavaina M; Apostolopoulou K
Scand J Gastroenterol; 2002 Jul; 37(7):863-5. PubMed ID: 12190104
[TBL] [Abstract][Full Text] [Related]
24. Management of peristomal pyoderma gangrenosum--two different approaches for the same clinical problem.
Javed A; Pal S; Ahuja V; Ramam M; Subbarao KC; Sahni P; Chattopadhyay TK
Trop Gastroenterol; 2011; 32(2):153-6. PubMed ID: 21922887
[No Abstract] [Full Text] [Related]
25. Clinical treatment options for peristomal pyoderma gangrenosum.
Vujnovich A
Br J Nurs; 2005 Sep 8-21; 14(16):S4-8. PubMed ID: 16215501
[TBL] [Abstract][Full Text] [Related]
26. Severe peristomal pyoderma gangrenosum: a case study.
Brady E
J Wound Ostomy Continence Nurs; 1999 Nov; 26(6):306-11. PubMed ID: 10865615
[TBL] [Abstract][Full Text] [Related]
27. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.
Guenova E; Teske A; Fehrenbacher B; Hoerber S; Adamczyk A; Schaller M; Hoetzenecker W; Biedermann T
Arch Dermatol; 2011 Oct; 147(10):1203-5. PubMed ID: 21680759
[TBL] [Abstract][Full Text] [Related]
28. Peristomal pyoderma gangrenosum: review and case study.
Brennecke A
Medsurg Nurs; 1996 Jun; 5(3):195-8, 217. PubMed ID: 8716587
[No Abstract] [Full Text] [Related]
29. Refractory pyoderma gangrenosum peristomal ulcer and sinus tract treated with micronized cadaveric dermis.
Levy D; Banta MR; Kirsner RS
J Am Acad Dermatol; 2005 Jun; 52(6):1104. PubMed ID: 15928642
[No Abstract] [Full Text] [Related]
30. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
[TBL] [Abstract][Full Text] [Related]
31. Peristomal Pyoderma Gangrenosum Responding to Risankizumab.
Weigelt MA; Kirsner RS
Adv Skin Wound Care; 2021 Jun; 34(6):327-329. PubMed ID: 33979822
[TBL] [Abstract][Full Text] [Related]
32. Auricular pyoderma gangrenosum associated with Crohn's disease.
Ben Chaabane N; Hellara O; Ben Mansour W; Ben Mansour I; Melki W; Loghmeri H; Safer L; Bdioui F; Saffar H
Tunis Med; 2012 May; 90(5):414-5. PubMed ID: 22585655
[No Abstract] [Full Text] [Related]
33. Rapid improvement of pyoderma gangrenosum after treatment with infliximab.
Chan JL; Graves MS; Cockerell CJ; Pandya AG
J Drugs Dermatol; 2010 Jun; 9(6):702-4. PubMed ID: 20645536
[TBL] [Abstract][Full Text] [Related]
34. Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease.
Hadziselimovic F
J Pediatr Gastroenterol Nutr; 2008 Feb; 46(2):208-11. PubMed ID: 18223382
[No Abstract] [Full Text] [Related]
35. Caring for the patient with peristomal pyoderma gangrenosum.
Stamm L; Swatske ME; Hickey S; Shephrd Z; Dalgaard J
J Wound Ostomy Continence Nurs; 1995 Sep; 22(5):237-41. PubMed ID: 7550780
[TBL] [Abstract][Full Text] [Related]
36. Pyoderma gangrenosum associated with inflammatory bowel disease. Report of two cases with good response to infliximab.
Carrasco Cubero C; Ruiz Tudela MM; Salaberri Maestrojuan JJ; Pérez Venegas JJ
Reumatol Clin; 2012; 8(2):90-2. PubMed ID: 22104047
[TBL] [Abstract][Full Text] [Related]
37. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab.
Goldminz AM; Botto NC; Gottlieb AB
J Am Acad Dermatol; 2012 Nov; 67(5):e237-8. PubMed ID: 23062936
[No Abstract] [Full Text] [Related]
38. Peristomal pyoderma gangrenosum associated with rectal adenocarcinoma.
Sakai H; Otsubo S; Iizuka H
J Dermatol; 2006 Jan; 33(1):68-70. PubMed ID: 16469090
[No Abstract] [Full Text] [Related]
39. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab.
Ljung T; Staun M; Grove O; Fausa O; Vatn MH; Hellström PM
Scand J Gastroenterol; 2002 Sep; 37(9):1108-10. PubMed ID: 12374238
[TBL] [Abstract][Full Text] [Related]
40. Ustekinumab in a patient with pyoderma gangrenosum and refractory Crohn's disease.
García Cámara P; Zubiri Ara ML; García López S
Med Clin (Barc); 2019 Oct; 153(8):e35-e36. PubMed ID: 30795905
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
